Correction: Fatal adverse events associated with programmed cell death ligand 1 inhibitors: a systematic review and meta-analysis
Abstract
• Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.Frontiers Media SA 2The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. Egger et al., 1997)."The corrected sentence appears below:"The funnel plot and Egger tests were used to estimate the publication bias of this study (Egger et al., 1997)."2. A correction has been made to the section 3 Results, Publication Bias, Paragraph Number 1. This sentence previously stated: "However, there was no evidence to prove publication bias existed in this study based on Begger's test (p = 0.57). Moreover, when 26 eligible studies and 44 ineligible ones were included in the analysis, there was a significant publication bias based on Begger's test (p < 0.0001)."The corrected sentence appears below:"There was publication bias existed in this study based on Egger test (p
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Pharmacovigilance and Adverse Drug Reactions
Meta-analysis and systematic reviews
Publication details
- Journal / source
- Frontiers in Pharmacology
- Volume
- 17
- Pages
- 1782058–1782058
- Publication date
- 17 February 2026
- Language
- EN